Ventyx Biosciences, Inc. (VTYX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Ventyx Biosciences (VTYX) is implementing AI algorithms and robotics to automate the discovery of immunological agents, minimizing manual labor. The business is based on creating unique small molecules designed to replace steroids in the treatment of autoimmune pathologies. However, a series of failed tests and R&D expenses are creating financial pressure. This price chart with the 0.00 indicator demonstrates the company's current valuation against the backdrop of pipeline risks.
ventyxbio.com - analytical breakdowns and key metrics (VTYX)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Ventyx Biosciences|VTYX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Ventyx Biosciences, Inc.|VTYX - Company Cumulative Debt|Debt to Book Value Ventyx Biosciences, Inc|VTYX - Company Long-Term Debt|Company Short-Term Debts Ventyx Biosciences|Quick Liquidity ventyxbio.com
- business earnings and investment ratios data:
VTYX - Company Profit|Future Profit Ventyx Biosciences|VTYX - Market Price to Net Income Ratio|Projected Price to Earnings Ventyx Biosciences|VTYX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Ventyx Biosciences, Inc|VTYX - Operating profit before amortization|Net earnings per share for the last 12 months Ventyx Biosciences|VTYX - Earnings per share for the trailing year|Quarterly EPS earnings growth ventyxbio.com|VTYX - Earnings per share growth in current year|Earnings growth forecast for next year Ventyx Biosciences
Initial company analysis:Ventyx Bio (VTYX)
Ventyx Biosciences focuses on a narrow segment of oral drugs for the therapy of autoimmune pathologies, which creates a high dependency on the success of specific developments. The EV/EBITDA metric compares the total enterprise value with its operating profitability before depreciation and taxes, determining the real value of the generated cash flow. This allows the investor to separate market noise from the fundamental stability of the capital structure. Analyzing the EV/EBITDA level over a time interval reveals whether the asset is overvalued or undervalued during periods of volatility.
Who Ventyx Biosciences competes with
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PHVS: EV/EBITDA Multiple|Company Value to EBITDA AbCellera (ABCL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tourmaline Bio|Enterprise Value to Operating Income Before Depreciation PGEN (Precigen Inc)|Enterprise Value to EBITDA Ratio PHAR (Pharming)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|Upstream Bio Inc - Enterprise Value to EBITDA Ratio|zenasbio.com (ZBIO) - Company Value to EBITDA|IMNM: Enterprise Value to EBITDA Ratio|GOSS (Gossamer Bio Inc) - Enterprise Value to Operating Income Before Depreciation|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Septerna Pharma - Business Value to Operating Income Before Depreciation|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SVRA|EV/EBITDA Multiple RIGL|Total Company Value to Operating Income Before Depreciation Ratio AnaptysBio Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Astria Pharma ATXS|enGene Corp (ENGN) - Company Value to EBITDA|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Aerovate Therapeutics Inc JBIO|ACRS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Kyverna Therapeutics Inc.|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|Cabaletta Bio Inc (CABA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THTX|AVTX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eledon Pharmaceuticals, Inc. ELDN|AGEN: Enterprise Value to Operating Income Before Depreciation|Climb Bio, Inc. - EV/EBITDA Multiple|zurabio.com (ZURA) - Enterprise Value to EBITDA Ratio|ATYR: EV/EBITDA Multiple|Company Value to EBITDA Adagene Inc. (ADAG)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImageneBio|Shattuck Therapeutics (STTK) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio EQ (Equillium, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CNTB (connectbiopharm.com)|Immunic - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ATRA (Atara Biotherapeutics, Inc.)|IFRX: Enterprise Value to EBITDA Ratio|Company Value to EBITDA X4 Pharmaceuticals Inc.|ACET (adicetbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation CELU|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|barinthusbio.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple KZR|SABS (SAB Biotherapeutics Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple AKTX (Akari Therapeutics plc)|EV/EBITDA Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation GOVX (geovax.com)|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio iBio Inc|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple XTL Bio|Enterprise Value to EBITDA Ratio BOLT (Bolt Biotherapeutics)|HCWB (hcwbiologics.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple APVO (Aptevo Therapeutics Inc.)|Total Company Value to Operating Income Before Depreciation Ratio aimimmuno.com (AIM)|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRI Bio Corporation (GRI) - Enterprise Value to EBITDA Ratio|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|Enterprise Value to EBITDA Ratio REVB|EV/EBITDA Multiple Indaptus Therapeutics Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|calcimedica.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AFMD (Affimed N.V.)|Allakos Inc (ALLK) - Company Value to EBITDA|HOOK: Enterprise Value to EBITDA Ratio|IGMS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ITOS: EV/EBITDA Multiple|Company Value to EBITDA Ocean Biomedical Corp (OCEA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
